

## LETTER OF ANNOUNCEMENT Stabilisation Period Overview Update


8<sup>th</sup> November 2022

We would like to share with you the latest overview of the stabilisation periods<sup>1</sup> throughout Europe.

Currently, for most of the countries (22), as illustrated on the map below, either the stabilisation period has ended (16) or was never implemented (6). Austria, Hungary and Portugal are currently in a phased or “stepped” approach to end their stabilisation period, meaning that the transition out of stabilisation period has been divided into several phases (for example by End-User category). For these three countries, the end date is under discussion with their NMVO Board and NCAs, respectively.

For the four (4) countries still in a stabilisation period, the timeframes are as follows:

- *Germany and Spain*: under discussion with the NCA;
- *Denmark*: until packs released prior to 9th Feb. 2019 expire;
- *France*: the stabilisation period will persist until the alert rate comes closer to 0,01% and is manageable by all parties.



<sup>1</sup> To allow a smooth transition to the FMD, some countries have opted to enter a “stabilisation” period, during which packs triggering alerts can still be dispensed to the patients, at the discretion of the pharmacists.



Tel. Helpdesk: **+32 (0)2 657 00 08**

E-Mail: [helpdesk@emvo-medicines.eu](mailto:helpdesk@emvo-medicines.eu)

**EMVO Team**

**European Medicines Verification Organisation**

[www.emvo-medicines.eu](http://www.emvo-medicines.eu)

[helpdesk@emvo-medicines.eu](mailto:helpdesk@emvo-medicines.eu)

EMVO © 2022. All rights reserved.

EMVO\_LoA\_0260